2. Search Result
Search Result
Results for "

long-term depression

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

5

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101955A
    (2R,6R)-Hydroxynorketamine hydrochloride

    (2R,6R)-HNK hydrochloride

    		 Drug Metabolite Neurological Disease
    (2R,6R)-Hydroxynorketamine ((2R,6R)-HNK) hydrochloride is an active ketamine metabolite with no NMDAR binding activity. (2R,6R)-Hydroxynorketamine hydrochloride rescues impaired dorsal hippocampal long-term potentiation and restores robust long-term potentiation in the hippocampal SC-CA1 pathway. (2R,6R)-Hydroxynorketamine hydrochloride can be used for research on depression .
    (2R,6R)-Hydroxynorketamine hydrochloride
  • HY-171844
    CX1739

    		iGluR Neurological Disease Inflammation/Immunology
    CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .
    CX1739
  • HY-P2259
    TAT-GluA2 3Y
    2 Publications Verification

    		 iGluR HIV Integrase Adenosine Receptor Cardiovascular Disease Neurological Disease
    TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .
    TAT-GluA2 3Y
  • HY-P4106A
    Tat-GluR23Y, scrambled TFA
    1 Publications Verification

    		 Amino Acid Derivatives Neurological Disease
    Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
    Tat-GluR23Y, scrambled TFA
  • HY-P4106
    Tat-GluR23Y, scrambled

    		Amino Acid Derivatives Neurological Disease
    Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
    Tat-GluR23Y, scrambled
  • HY-P1058
    Pep2m

    		iGluR Neurological Disease
    Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression [1] [2] [3] [4] [5].
    Pep2m
  • HY-P1056
    pep2-SVKI

    		iGluR Neurological Disease
    pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases .
    pep2-SVKI
  • HY-181127
    GluN2B-NMDAR Allosteric modulator 1

    		iGluR Neurological Disease
    GluN2B-NMDAR Allosteric modulator 1 is a selective GluN2B-NMDAR positive allosteric modulator. GluN2B-NMDAR Allosteric modulator 1 can increase glutamate- and aspartate-evoked GluN2B-NMDAR-gated currents with EC50 values of 43.7 and 18 nM. GluN2B-NMDAR Allosteric modulator 1 can reverse anxiety-like behavior and social cognition deficits in mice. GluN2B-NMDAR Allosteric modulator 1 can be used for the research of neurological disease, such as anxiety .
    GluN2B-NMDAR Allosteric modulator 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: